Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Olema Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
OLMA
Nasdaq
2836
olema.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Olema Pharmaceuticals, Inc.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 4th, 2025 9:30 pm
Olema Oncology to Participate in Upcoming Investor Conferences
- Feb 3rd, 2025 9:30 pm
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2025 12:00 pm
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
- Dec 10th, 2024 12:00 pm
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
- Dec 9th, 2024 12:00 pm
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
- Dec 3rd, 2024 6:37 pm
Novartis and Olema expand alliance with $250m to boost breast cancer trials
- Dec 3rd, 2024 2:17 pm
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement
- Dec 2nd, 2024 1:08 pm
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
- Dec 2nd, 2024 12:00 pm
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
- Nov 25th, 2024 10:30 pm
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
- Nov 25th, 2024 12:27 am
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 12th, 2024 9:01 pm
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
- Oct 31st, 2024 12:57 pm
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
- Oct 23rd, 2024 11:00 am
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Oct 9th, 2024 11:00 am
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
- Aug 21st, 2024 11:00 am
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 6th, 2024 8:02 pm
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
- Aug 1st, 2024 12:50 pm
Olema Oncology to Participate in Upcoming Investor Conferences in June
- May 28th, 2024 11:03 am
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
- May 24th, 2024 12:08 pm
Scroll